Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells
Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen but also through Fc domain-mediated recruitment... Read More
Webinar Recap: Unlocking GPCR’s for Oncology
Surprisingly few GPCR-targeted therapies have been developed for oncology, despite frequent disregulation of the receptors and their signaling mediators that control pro-survival... Read More
Discovering a New Class of Anti-Cancer Compounds
Oncoceutics, Inc. is a clinical-stage biotech company developing a novel class of small molecule compounds for oncology called imipridones that selectively target... Read More